tbuckley/cabot-search huggingface dataset:
Abstract 4646: Loss of nuclear HoxA10 is associated with proliferation of testicular germ cell tumors
Authors: RuiQi Chen, Haolong Li, Yinan Li, Ladan Fazli, Martin Gleave, Lucia Nappi, Xuesen Dong
Journal: Cancer Research (2019)

Abstract Background: HOXA10 is a key transcriptional factor that regulates testis development as reported from previous transgenic mouse models and human inherited diseases. However, whether it also plays important roles in promoting the development of testicular cancer is not well understood. Objective: To study the expression of HOXA10 and its regulated signaling pathways in testicular cancers. Design, Setting, and Participants: A tissue microarray was constructed with benign and cancerous testis. TCam2, NT-2, and NCCIT cell models were applied in this study. Intervention: Immunohistochemistry and immunofluorescence were performed to measure the expression and cellular localization of HOXA10 in testicular cancer tissues and cell models. Cell proliferation and cell cycling rates were determined by BrdU incorporation and flow cytometry assays. HOXA10 transcriptomes were profiled with Ampliseq RNA-seq in testicular cancer cells. Immunoblotting assays were used to detect HOXA10-regulated signaling. Results: HOXA10 is a nuclear protein in benign spermatocytes. Reduced nuclear expression and increased cytoplasmic expression of HOXA10 are associated with testicular cancers. These changes are consistent in both seminoma and non-seminoma. Enhanced HOXA10 expression in testicular cancer cell models inhibits cell proliferation and delays cell cycle progression through G2/M phases. These functions of HOXA10 mainly affect the TP53, cKit, STAT3, AKT and ERK signaling pathways. Conclusions: Loss of nuclear functions of HOXA10 enhances proliferation of testicular cancer cells, suggesting that downregulation of HOXA10 transcription activity may promote the development of testicular cancers. Citation Format: RuiQi Chen, Haolong Li, Yinan Li, Ladan Fazli, Martin Gleave, Lucia Nappi, Xuesen Dong. Loss of nuclear HoxA10 is associated with proliferation of testicular germ cell tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4646.
Fraser Brockington
Journal: BMJ (2005)

Founder of the Northern Ireland Renal ServiceMollie McGeown overcame gender prejudice in 1950s Northern Ireland medicine to build a career that changed the lives of thousands of people affected by kidney failure.After completing an MD thesis on endocarditis followed by a PhD in biochemistry, she was awarded a five year Medical Research Council fellowship and went on to develop an international reputation in calcium metabolism, hyperparathyroidism, and kidney stone disease.In 1959 she was appointed to set up a dialysis service for Northern Ireland and carried out the first successful dialysis on a uraemic patient later that year.This was a pivotal moment for patients in Northern Ireland with kidney failure.Over 200 patients in Northern Ireland at that time died each year from this cause.In 1971 a young woman treated by Mollie for pregnancy related renal failure founded the Northern Ireland Kidney Research Fund, which has to date raised £3m (€4.38m; $5.6m).Mollie was the patron of this fund up to her death.
Current Issues in the Epidemiology and Toxicology of Occupational Exposure to Lead
Authors: Philip J. Landrigan
Journal: Environmental Health Perspectives (1990)

Occupational exposure to lead is widespread in the United States. Clinically evident lead poisoning as well as subclinical toxicity occur in populations with occupational lead exposure. The focus of current research on lead toxicity in industrial populations is in the definition of dose-response relationships, particularly at low levels of exposure. Major interest surrounds the development of biochemical and physiologic markers of subclinical toxicity. Need exists to better delineate the toxicity of lead on the peripheral and central nervous system, the kidneys, the cardiovascular system, and the reproductive organs using newly developed markers. To obtain more accurate information on cumulative individual exposure to lead, future research on lead toxicity will increasingly use X-ray fluorescence analysis for determination of the lead content in home.
St. Luke's Hospital.
Authors: Fred R. Belknap
Journal: JAMA (1901)

Literature will be distributed and a magazine in the interests of vaccination will probably be started.Lectures may also form a feature of the league's propaganda. Hematuria in Childhood.At the Harveian Society Mr. Campbell Williams read a short but very exhaustive paper on this subject.He pointed out that in many eases of calculus hematuria was absent, the only diagnostic signs being dysuria and frequent micturition.The first symptom of renal tuberculosis might be copious hema¬ turia.
Shoelaces
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Harkin DE, Beall AC Jr,+BEALL AC JR: Excerpts and summary of a National Conference on Medical Devices. Bethesda, Md., Sept 6 and 7, 1969
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Prospective Phase II Trial of Lenalidomide and Dexamethasone ( LEN-DEX) in POEMS Syndrome
Authors: Arnaud Jaccard, Anne Lazareth, Lionel Karlin, Sylvain Choquet, Laurent Frenzel, Laurent Garderet, Mamoun Dib, Lionel Galicier, Olivier Tournilhac, Karim Belhadj, Philippe Moreau, Olivier Decaux, Lotfi Benboubker, Michel Cogné, Lucile Musset, Jean Paul Fermand
Journal: Blood (2014)
Contribution of Sulfonylureas to Elucidation of Hepatic Action of Insulin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome of Pregnancy After Induced Ovulation
Authors: M. Hack
Journal: JAMA (1970)

Of 78 pregnancies after ovulation induced by menotropins and chorionic gonadotropin, 47 single, 23 twin, 5 triplet, 2 quadruplet, and 1 sextuplet births occurred. There was an abortion rate of 29% and a high multiple birth rate of 37.7% in patients who reached at least 20 weeks of pregnancy. The secondary sex ratio (M:F) in single births was 0.88; the sex ratio for births of twins was significantly lower (0.43). Only two of 23 twin births were male-male. The occurrence of multiple births probably caused the early delivery and corresponding fetal and neonatal loss of these infants (27%). The infants who died weighed less than 2,000 gm (4.4 lb) and were under 224 days gestation. Birth weight related to gestational age from day of ovulation was normal. The postnatal growth and development of the children were normal. The incidence of congenital malformations was within the normal range.
Pseudoaccountability
Authors: Richard R. Babb
Journal: Annals of Internal Medicine (2002)

Letters16 April 2002PseudoaccountabilityRichard R. Babb, MDRichard R. Babb, MDPalo Alto Medical Clinic; Palo Alto, CA 94301 (Babb)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-8-200204160-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Kassirer (1) writes that efforts by the medical profession to self-regulate its practices have been poor and uneven; he suggests turning the job over to an independent, disinterested, and outside group. Our experience with self-regulation leads us to a different conclusion.The Palo Alto Medical Clinic is a multispecialty clinic with 240 physicians. To assure ourselves and the public that we provide the highest possible quality of care, we have established the following committees. Department heads and the professional affairs committee examine the work of each physician every 1 to 2 years by reviewing charts and questioning ...Reference1. Kassirer JP. Pseudoaccountability. Ann Intern Med. 2001;134:587-90. [PMID: 11281741] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Richard R. Babb, MDAffiliations: Palo Alto Medical Clinic; Palo Alto, CA 94301 (Babb) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPseudoaccountability Jerome P. Kassirer Metrics 16 April 2002Volume 136, Issue 8 Page: 631 Keywords Alcoholism Charts Drug abuse Drugs Emotions Health care quality Health care quality assessment Preventive medicine Risk management ePublished: 16 April 2002 Issue Published: 16 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
DISCUSSION ON PAPER OF DR. D. L. ROCHESTER, OF BUFFALO, ON "THE PROGNOSIS AND THERAPEUTIC INDICATIONS IN HEART DISEASE."
Journal: JAMA (1897)

Dr. J. B.Herrickof Chicago—I rise to say a word for one method of treatment which has passed somewhat out of fashion—venesection. The benefit of this method has been brought home to me in three cases of cardiac dilatation where the dilatation was due apparently to fibrous myocarditis. The patients entered the hospital with extreme dyspnea, amounting to orthopnea, extreme cyanosis, edema, with feeble arhythmic pulse, feeble heart sounds, and with systolic murmurs believed to be connected with the mitral and tricuspid valves. In these cases, believing that stimulation of the heart would not do as much good as relief from the work which the heart was required to do, abstraction of eight to sixteen ounces of blood was practiced, and in all three of these cases with the most gratifying results, in one temporary, in the other two more permanent. So I would speak favorably of treatment by
Questions and Answers
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Publishing
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease
Authors: M. Ghidini, J.C. Hahne, C. Senti, A. Lampis, M. Ratti, C. Pizzo, G. Tomasello, R. Passalacqua, N. Valeri
Journal: Annals of Oncology (2019)
AMA Insights
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cuthbert Esquire Dukes (1890--1977)
Journal: CA A Cancer Journal for Clinicians (1978)

terest in this field continued throughout his life.In1925hepublished a book on thebac teriobogy of food; this was followed, in 1939and 1946respectively, by bookson the examination and interpretation of urine and bacteria related to nursing.Dr. Dukes also had a lifelong interest in patients with colostomies and ileosto mies, and he invested considerable time and energy in improving theirmanage ment and lessening their discomfort.His cdncern was so great that he visited scores of colostomy patients at their homes, in order to better understand their problems and needs, and he was an active advisor to the bleostomy Association of Great Bri tain from the time of its formation.One of his primary contributions in this area was his demonstration that the stoma could work spontaneously, without the incon venience of frequent washouts.
On Laughter
Authors: Art Buchwald
Journal: JAMA (1984)

I am delighted that the American Medical Association is starting to take laughter seriously. As Dr W. Black points out in his learned paper,<sup>1</sup>laughter does have a great therapeutic value in a person's health. The more a person laughs (voluntarily as opposed to involuntarily), the better he feels. Dr Black cites many studies that indicate what takes place physiologically in the body when we laugh, but there is still a lot of scientific work to be done before the Food and Drug Administration will permit it to be used in large doses. Once it is approved as a prescription drug (let's hope they never allow it to be sold over the counter), the biggest question is whether we can provide enough of the product to fulfill the needs of all people who are in need of it. While Dr Black covers the subject thoroughly, he still leaves many
Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE
Authors: S.L. Klijn, J.M.P.A. van den Reek, G. van de Wetering, A. van der Kolk, E.M.G.J. de Jong, W. Kievit
Journal: British Journal of Dermatology (2018)

Psoriasis is a chronic inflammatory skin condition. It can be unsightly and uncomfortable, significantly affecting quality of life. It is usually treated with regular applications of creams, but more severe psoriasis requires immune‐suppressive medication given by mouth or injection. Newer, targeted “biologic” drugs are more effective but expensive, and cost‐benefit data is limited. Patients in the real world often differ from those selected for randomised control trials (RCTs) in having additional illnesses, and are often switched from one drug to another to improve efficacy or reduce side‐effects; there is no evidence to inform clinicians about what order to use them in. This industry‐sponsored study from Holland analysed the cost‐effectiveness of three biologic drugs, adalimumab, etanercept and ustekinumab, given in different sequences over 10 years. A computerised simulation used published information on drug and monitoring costs and “real world evidence” from 318 patients already enrolled in a Dutch registry called BioCAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry with Biologics) which includes quality of life scores as well as clinical outcomes (i.e. symptoms) and details of treatment. Mean age at enrolment was 47 years, mean body weight 87 kg and mean biologic treatment course duration 29.6 months. They estimated that treatment of psoriasis with these biologics for ten years costs €141,962 to €148,442 per patient. Starting with adalimumab or ustekinumab rather than etanercept costs somewhat less for each additional year in perfect health, even when modelled using cheaper “biosimilars”, and is thus considered advantageous in health‐economic terms, at least within an academic centre.
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer
Authors: Jennifer Cullen, Inger L. Rosner, Timothy C. Brand, Nan Zhang, Athanasios C. Tsiatis, Joel Moncur, Amina Ali, Yongmei Chen, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Phillip G. Febbo, Shiv Srivastava, Isabell A. Sesterhenn, David G. McLeod
Journal: European Urology (2014)

Biomarkers that are validated in independent cohorts are needed to improve risk assessment for prostate cancer (PCa).A racially diverse cohort of men (20% African American [AA]) was used to evaluate the association of the clinically validated 17-gene Genomic Prostate Score (GPS) with recurrence after radical prostatectomy and adverse pathology (AP) at surgery.Biopsies from 431 men treated for National Comprehensive Cancer Network (NCCN) very low-, low-, or intermediate-risk PCa between 1990 and 2011 at two US military medical centers were tested to validate the association between GPS and biochemical recurrence (BCR) and to confirm the association with AP. Metastatic recurrence (MR) was also evaluated.Cox proportional hazards models were used for BCR and MR, and logistic regression was used for AP. Central pathology review was performed by one uropathologist. AP was defined as primary Gleason pattern 4 or any pattern 5 and/or pT3 disease.GPS results (scale: 0-100) were obtained in 402 cases (93%); 62 men (15%) experienced BCR, 5 developed metastases, and 163 had AP. Median follow-up was 5.2 yr. GPS predicted time to BCR in univariable analysis (hazard ratio per 20 GPS units [HR/20 units]: 2.9; p<0.001) and after adjusting for NCCN risk group (HR/20 units: 2.7; p<0.001). GPS also predicted time to metastases (HR/20 units: 3.8; p=0.032), although the event rate was low (n=5). GPS was strongly associated with AP (odds ratio per 20 GPS units: 3.3; p<0.001), adjusted for NCCN risk group. In AA and Caucasian men, the median GPS was 30.3 for both, the distributions of GPS results were similar, and GPS was similarly predictive of outcome.The association of GPS with near- and long-term clinical end points establishes the assay as a strong independent measure of PCa aggressiveness. Tumor aggressiveness, as measured by GPS, and outcomes were similar in AA and Caucasian men in this equal-access health care system.Predicting outcomes in men with newly diagnosed prostate cancer is challenging. This study demonstrates that a new molecular test, the Genomic Prostate Score, which can be performed on a patient's original prostate needle biopsy, can predict the aggressiveness of the cancer and help men make decisions regarding the need for immediate treatment of their cancer.